GLP-1 agonists, drugs like Novo Nordisk A/S’s (NYSE:NVO) Ozempic, Wegovy, and Eli Lilly And Co’s (NYSE:LLY) Zepbound, have revolutionized the treatment of obesity and diabetes. Now, researchers are investigating their potential to address a range of other conditions, including addiction, sleep apnea, and even cancer. These medications are showing early promise in preventing several common cancers linked to obesity, such as breast, colon, liver, and ovarian cancers, by acting on the brain to regulate hormones, slow digestion, and reduce hunger. Also Read: Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks. While research on GLP-1 drugs is still in its early stages, studies indicate their potential to reduce cancer risks, NPR report notes. For ...